NIHR boosts research funding in Scotland, Northern Ireland, and Wales
11 Jul 2023
Researchers in Scotland, Northern Ireland and Wales will be able to access further funding from the National Institute for Health and Care Research (NIHR) from autumn 2023.
Health and social care researchers and in some cases SMEs in the devolved administrations (DAs) will have increased access to health and social care research funding via the NIHR. The move has been agreed following consultation with the Scottish Government’s Chief Scientist Office, Health and Care Research Wales and Health and Social Care Research & Development in Northern Ireland.
The announcement expands the list of NIHR research programmes that are available to researchers in Scotland, Wales and Northern Ireland. The move will boost cross-UK research and help increase access to research for people in the three devolved administrations.
The NIHR, through DHSC, has had an arrangement with the DAs since 2008 based on investments from each nation that has allowed research hosts (including universities and research active NHS organisations) in the three nations to apply for NIHR funding from four research programmes (Health Technology Assessment (HTA), Health and Social Care Delivery Research (HSDR), Public Health Research (PHR), and Efficacy and Mechanism Evaluation (EME) that would otherwise only be open to English research hosts.
Expanding the reach of NIHR funding
A new partnership funding arrangement has been agreed that will provide greater access to NIHR research programmes, with the door open to further cross-UK working on funded research in future.
Researchers and in some cases, SMEs will be able to access five further NIHR research programmes from autumn 2023:
Evidence Synthesis
Invention for Innovation (i4i)
Research for Social Care (RfSC)
Programme Grants for Applied Research programme (PGfAR)
Programme Development Grants
The new funding arrangements will facilitate more cross-UK research, similar to the successful COVID research collaborations seen during the pandemic. The change will also increase opportunities for researchers in the three devolved nations to collaborate with industry, including pharmaceutical companies and the medical technology industry. The shift in funding eligibility recognises the fact that health and social care research is typically conducted across all four UK nations and is more powerful and efficient as a result.
NIHR’s Policy Research Programme remains open to applications from researchers in the devolved nations but the programme and its funded research is focused on English policy needs.
Professor Dame Anna Dominiczak, chief scientist (health) for Scotland said: “The Chief Scientist Office welcomes the increased access to the NIHR Research Funding Programmes for researchers based in Scotland. I am confident that these programmes will see many high-quality applications from Scotland going forward.”
Professor Ian Young, chief scientific advisor and director of Health and Social Care Research and Development commented: “The extended access to NIHR funding programmes represents a welcome increase in opportunities for Northern Ireland-based researchers to lead studies across the range of health and social care priorities, and, importantly, for more of our citizens to participate in an expanded range of research initiatives. I look forward to our research community building on the successes to date, producing evidence on which to base future practice, and to our indigenous SMEs benefitting from the new opportunities specifically provided by the i4i Programme.”
Professor Kieran Walshe, director of Health and Care Research Wales, added: “We are delighted with the expansion of our current agreement and the access to a greater range of NIHR funding programmes that this will bring. The new partnership arrangements will increase opportunities for researchers in Wales to both lead and participate in studies of UK significance, while strengthening health and care research in the UK across the four nations.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.